Celgene Corp. (NASDAQ:CELG)

The data reflects significant fluctuations and trends in the financial performance over the period analyzed.

Operating Income (Loss)

The operating income demonstrates a generally upward trajectory from 2005 through 2018, with the exception of a substantial loss in 2008. Initially, the values start modestly at 84 million US dollars in 2005, peaking at 425 million in 2007. The sharp decline to a loss of 1,464 million in 2008 marks an anomaly, likely attributable to extraordinary expenses or one-time charges. Following this setback, the operating income recovers robustly, increasing steadily year-over-year to reach 5,191 million US dollars by 2018.

Net Product Sales

Net product sales exhibit consistent and strong growth over the entire period. Beginning at 446 million US dollars in 2005, sales nearly double by 2006, followed by sustained growth each subsequent year. By 2018, net product sales attain 15,265 million US dollars, representing more than a 34-fold increase compared to 2005. This trend signifies a successful expansion in market reach, product acceptance, or pricing power.

Operating Profit Margin

The operating profit margin generally reflects positive profitability, with a notable exception in 2008. From 2005 until 2007, margins range narrowly between 18.76% and 32.69%, indicating effective cost management and profitability relative to sales. The margin plunges sharply to -68.5% in 2008, coinciding with the operating loss recorded in the same year, signaling an extraordinary negative impact on profitability. Post-2008, the margin recovers, fluctuating in the 24.61% to 36.28% range. The highest margin occurs in 2017 at 36.28%, suggesting improved operational efficiency or favorable product mix, while the margin remains strong in 2018 at 34.01%.